The DOI matches its Crossref record; 151 of the 151 references it cites were found in a registry or an index.
PPARs: Regulators of Metabolism and As Therapeutic Targets in Cardiovascular disease. Part II: PPAR-β/δ and PPAR-γ
Open accessAbstract
The PPARs are a subfamily of three ligand-inducible transcription factors, which belong to the superfamily of nuclear hormone receptors. In mammals, the PPAR subfamily consists of three members: PPAR-α, PPAR-β/δ and PPAR-γ. PPARs control the expression of a large number of genes involved in metabolic homeostasis, lipid, glucose and energy metabolism, adipogenesis and inflammation. PPARs regulate a large number of metabolic pathways that are implicated in the pathogenesis of metabolic diseases such as metabolic syndrome, Type 2 diabetes mellitus, nonalcoholic fatty liver disease and cardiovascular disease. The aim of this review is to provide up-to-date information about the biochemical and metabolic actions of PPAR-β/δ and PPAR-γ, the therapeutic potential of their agonists currently under clinical development and the cardiovascular disease outcome of clinical trials of PPAR-γ agonists, pioglitazone and rosiglitazone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ng, M., Fleming, T., Robinson, M., Thomson, B., Graetz, N., Margono, C., Mullany, E. C., Biryukov, S., Abbafati, C., Abera, S. F., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60460-8 · Cited by 11,952
Eckel, R. H., Alberti, K., Grundy, S. M., & Zimmet, P. Z. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61794-3 · Cited by 6,295
Adipokines in inflammation and metabolic disease
Ouchi, N., Parker, J. L., Lugus, J. J., & Walsh, K. (2011) · Nature Reviews Immunology · doi:10.1038/nri2921 · Cited by 4,625
Zhou, B., Lu, Y., Hajifathalian, K., Bentham, J., Di Cesare, M., Danaei, G., Bixby, H., Cowan, M., Ali, M., Taddei, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00618-8 · Cited by 4,311
Mechanisms of fatty acid-induced inhibition of glucose uptake.
Boden, G., Chen, X., Ruiz, J., White, J. V., & Rossetti, L. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117252 · Cited by 3,705
Poirier, P., Giles, T. D., Bray, G. A., Hong, Y., Stern, J. S., Pi-Sunyer, F. X., & Eckel, R. H. (2006) · Circulation · doi:10.1161/circulationaha.106.171016 · Cited by 3,165
Byrne, C. D., & Targher, G. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.12.012 · Cited by 3,042
The mechanisms of action of PPARs
Berger, J., & Moller, D. E. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104018 · Cited by 2,659
Adipocyte differentiation from the inside out
Rosen, E. D., & MacDougald, O. A. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2066 · Cited by 2,607
Obesity and Cardiovascular Disease
Lavie, C. J., Milani, R. V., & Ventura, H. O. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.12.068 · Cited by 2,326
Braissant, O., Foufelle, F., Scotto, C., Dauça, M., & Wahli, W. (1996) · Endocrinology · doi:10.1210/endo.137.1.8536636 · Cited by 2,217
Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications
Fabbrini, E., Sullivan, S., & Klein, S. (2010) · Hepatology · doi:10.1002/hep.23280 · Cited by 2,100
Fat and Beyond: The Diverse Biology of PPARγ
Tontonoz, P., & Spiegelman, B. M. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.061307.091829 · Cited by 2,085
PPARγ signaling and metabolism: the good, the bad and the future
Ahmadian, M., Suh, J. M., Hah, N., Liddle, C., Atkins, A. R., Downes, M., & Evans, R. M. (2013) · Nature Medicine · doi:10.1038/nm.3159 · Cited by 2,016
Roles of PPARs in health and disease
Kersten, S., Desvergne, B., & Wahli, W. (2000) · Nature · doi:10.1038/35013000 · Cited by 1,956
Transcriptional control of adipocyte formation
Farmer, S. R. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.07.001 · Cited by 1,831
Yki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism
Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
Anstee, Q. M., Targher, G., & Day, C. P. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.41 · Cited by 1,747
Loomba, R., & Sanyal, A. J. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.171 · Cited by 1,641
Global obesity: trends, risk factors and policy implications
Malik, V. S., Willett, W. C., & Hu, F. B. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.199 · Cited by 1,408
Kliewer, S. A., Forman, B. M., Blumberg, B., Ong, E. S., Borgmeyer, U., Mangelsdorf, D. J., Umesono, K., & Evans, R. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.15.7355 · Cited by 1,400
Forming functional fat: a growing understanding of adipocyte differentiation
Cristancho, A. G., & Lazar, M. A. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3198 · Cited by 1,382
Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome
Yki-Järvinen, H. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70032-4 · Cited by 1,259
Peroxisome proliferator-activated receptor a target genes
Mandard, S., M�ller, M., & Kersten, S. (2004) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s00018-003-3216-3 · Cited by 1,218
Obesity and Cardiovascular Disease
Ortega, F. B., Lavie, C. J., & Blair, S. N. (2016) · Circulation Research · doi:10.1161/circresaha.115.306883 · Cited by 1,202
The Organization, Promoter Analysis, and Expression of the Human PPARγ Gene
Fajas, L., Auboeuf, D., Raspé, E., Schoonjans, K., Lefebvre, A.-M., Saladin, R., Najib, J., Laville, M., Fruchart, J.-C., Deeb, S., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.30.18779 · Cited by 1,188
Benson, S. C., Pershadsingh, H. A., Ho, C. I., Chittiboyina, A., Desai, P., Pravenec, M., Qi, N., Wang, J., Avery, M. A., & Kurtz, T. W. (2004) · Hypertension · doi:10.1161/01.hyp.0000123072.34629.57 · Cited by 1,073
Chawla, A., Barak, Y., Nagy, L., Liao, D., Tontonoz, P., & Evans, R. M. (2001) · Nature Medicine · doi:10.1038/83336 · Cited by 1,069
Oliver, W. R., Shenk, J. L., Snaith, M. R., Russell, C. S., Plunket, K. D., Bodkin, N. L., Lewis, M. C., Winegar, D. A., Sznaidman, M. L., Lambert, M. H., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091021198 · Cited by 1,046
International Union of Pharmacology. LXI. Peroxisome Proliferator-Activated Receptors
Michalik, L., Auwerx, J., Berger, J. P., Chatterjee, V. K., Glass, C. K., Gonzalez, F. J., Grimaldi, P. A., Kadowaki, T., Lazar, M. A., O’Rahilly, S., et al. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.4.5 · Cited by 1,000
Sorting out the roles of PPAR in energy metabolism and vascular homeostasis
Lefebvre, P. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27989 · Cited by 962
Epidemiology of Obesity and Diabetes and Their Cardiovascular Complications
Bhupathiraju, S. N., & Hu, F. B. (2016) · Circulation Research · doi:10.1161/circresaha.115.306825 · Cited by 945
Grundy, S. M. (2016) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2015.10.004 · Cited by 882
Li, A. C., Brown, K. K., Silvestre, M. J., Willson, T. M., Palinski, W., & Glass, C. K. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10370 · Cited by 833
PPAR and human metabolic disease
Semple, R. K. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28003 · Cited by 827
Goldberg, R. B., Kendall, D. M., Deeg, M. A., Buse, J. B., Zagar, A. J., Pinaire, J. A., Tan, M. H., Khan, M. A., Perez, A. T., Jacober, S. J., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1547 · Cited by 795
Obesity, Inflammation, and Cancer
Deng, T., Lyon, C. J., Bergin, S., Caligiuri, M. A., & Hsueh, W. A. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044359 · Cited by 794
PPARs in Obesity-Induced T2DM, Dyslipidaemia and NAFLD
Gross, B., Pawlak, M., Lefebvre, P., & Staels, B. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.135 · Cited by 778
PPARs: therapeutic targets for metabolic disease
Berger, J. P., Akiyama, T. E., & Meinke, P. T. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.03.003 · Cited by 713
Auboeuf, D., Rieusset, J., Fajas, L., Vallier, P., Frering, V., Riou, J. P., Staels, B., Auwerx, J., Laville, M., & Vidal, H. (1997) · Diabetes · doi:10.2337/diab.46.8.1319 · Cited by 697
Nonalcoholic fatty liver disease: A precursor of the metabolic syndrome
Lonardo, A., Ballestri, S., Marchesini, G., Angulo, P., & Loria, P. (2015) · Digestive and Liver Disease · doi:10.1016/j.dld.2014.09.020 · Cited by 685
Metabolic Syndrome: Connecting and Reconciling Cardiovascular and Diabetes Worlds
Grundy, S. M. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.11.046 · Cited by 679
PPARs at the crossroads of lipid signaling and inflammation
Wahli, W., & Michalik, L. (2012) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2012.05.001 · Cited by 675
Integrated physiology and systems biology of PPARα
Kersten, S. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.02.002 · Cited by 670
PPARγ and the global map of adipogenesis and beyond
Lefterova, M. I., Haakonsson, A. K., Lazar, M. A., & Mandrup, S. (2014) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2014.04.001 · Cited by 623
Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum
Hardy, T., Oakley, F., Anstee, Q. M., & Day, C. P. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044224 · Cited by 611
Li, A. C., Binder, C. J., Gutierrez, A., Brown, K. K., Plotkin, C. R., Pattison, J. W., Valledor, A. F., Davis, R. A., Willson, T. M., Witztum, J. L., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci18730 · Cited by 573
The Metabolic Syndrome: Inflammation, Diabetes Mellitus, and Cardiovascular Disease
Haffner, S. M. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.11.010 · Cited by 560
Obesity and Type 2 Diabetes: What Can Be Unified and What Needs to Be Individualized?
Eckel, R. H., Kahn, S. E., Ferrannini, E., Goldfine, A. B., Nathan, D. M., Schwartz, M. W., Smith, R. J., & Smith, S. R. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0585 · Cited by 552
Nguyen, D. M., & El-Serag, H. B. (2010) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2009.12.014 · Cited by 531
Sayiner, M., Koenig, A., Henry, L., & Younossi, Z. M. (2016) · Clinics in Liver Disease · doi:10.1016/j.cld.2015.10.001 · Cited by 529
PPARδ regulates glucose metabolism and insulin sensitivity
Lee, C.-H., Olson, P., Hevener, A., Mehl, I., Chong, L.-W., Olefsky, J. M., Gonzalez, F. J., Ham, J., Kang, H., Peters, J. M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511253103 · Cited by 497
Differential activation of adipogenesis by multiple PPAR isoforms.
Brun, R. P., Tontonoz, P., Forman, B. M., Ellis, R., Chen, J., Evans, R. M., & Spiegelman, B. M. (1996) · Genes & Development · doi:10.1101/gad.10.8.974 · Cited by 474
Medical significance of peroxisome proliferator-activated receptors
Vamecq, J., & Latruffe, N. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10364-1 · Cited by 468
Potent Inhibitory Effect of Troglitazone on Carotid Arterial Wall Thickness in Type 2 Diabetes
Minamikawa, J. (1998) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.5.1818 · Cited by 461
Modulation of PPAR activity via phosphorylation
BURNS, K., & VANDENHEUVEL, J. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.04.018 · Cited by 443
Staels, B., Rubenstrunk, A., Noel, B., Rigou, G., Delataille, P., Millatt, L. J., Baron, M., Lucas, A., Tailleux, A., Hum, D. W., et al. (2013) · Hepatology · doi:10.1002/hep.26461 · Cited by 414
The mode of action of thiazolidinediones
Hauner, H. (2002) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.249 · Cited by 411
Krishnan, J., Suter, M., Windak, R., Krebs, T., Felley, A., Montessuit, C., Tokarska-Schlattner, M., Aasum, E., Bogdanova, A., Perriard, E., et al. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.05.005 · Cited by 404
Collins, A. R., Meehan, W. P., Kintscher, U., Jackson, S., Wakino, S., Noh, G., Palinski, W., Hsueh, W. A., & Law, R. E. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.21.3.365 · Cited by 385
PPARα: Energy Combustion, Hypolipidemia, Inflammation and Cancer
Pyper, S. R., Viswakarma, N., Yu, S., & Reddy, J. K. (2010) · Nuclear Receptor Signaling · doi:10.1621/nrs.08002 · Cited by 379
Peroxisome proliferator-activated receptors and inflammation
Moraes, L. A., Piqueras, L., & Bishop-Bailey, D. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.08.007 · Cited by 376
Cloning of a Protein That Mediates Transcriptional Effects of Fatty Acids in Preadipocytes
Amri, E.-Z., Bonino, F., Ailhaud, G., Abumrad, N. A., & Grimaldi, P. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.5.2367 · Cited by 368
PPARs: diverse regulators in energy metabolism and metabolic diseases
Wang, Y.-X. (2010) · Cell Research · doi:10.1038/cr.2010.13 · Cited by 366
Nonalcoholic fatty liver disease: A manifestation of the metabolic syndrome
KIM, C. H., & YOUNOSSI, Z. M. (2008) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.75.10.721 · Cited by 340
Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment
Smith, B. W., & Adams, L. A. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.72 · Cited by 327
Chen, Z., Ishibashi, S., Perrey, S., Osuga, J.-I., Gotoda, T., Kitamine, T., Tamura, Y., Okazaki, H., Yahagi, N., Iizuka, Y., et al. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.21.3.372 · Cited by 320
Emerging roles of the corepressors NCoR1 and SMRT in homeostasis
Mottis, A., Mouchiroud, L., & Auwerx, J. (2013) · Genes & Development · doi:10.1101/gad.214023.113 · Cited by 297
Obesity and Cancer: Local and Systemic Mechanisms
Iyengar, N. M., Hudis, C. A., & Dannenberg, A. J. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-050913-022228 · Cited by 281
Peroxisome Proliferator-Activated Receptor-γ–Mediated Effects in the Vasculature
Duan, S. Z., Usher, M. G., & Mortensen, R. M. (2008) · Circulation Research · doi:10.1161/circresaha.107.164384 · Cited by 263
Fruchart, J.-C. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.03.008 · Cited by 233
Coactivators in PPAR-Regulated Gene Expression
Viswakarma, N., Jia, Y., Bai, L., Vluggens, A., Borensztajn, J., Xu, J., & Reddy, J. K. (2010) · PPAR Research · doi:10.1155/2010/250126 · Cited by 229
The PPAR regulatory system in cardiac physiology and disease
FINCK, B. (2007) · Cardiovascular Research · doi:10.1016/j.cardiores.2006.08.023 · Cited by 223
PPARγ-mediated insulin sensitization: the importance of fat versus muscle
Kintscher, U., & Law, R. E. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00440.2004 · Cited by 220
Transcriptional and epigenetic regulation of PPARγ expression during adipogenesis
Lee, J.-E., & Ge, K. (2014) · Cell & Bioscience · doi:10.1186/2045-3701-4-29 · Cited by 219
Abbott, B. D. (2009) · Reproductive Toxicology · doi:10.1016/j.reprotox.2008.10.001 · Cited by 218
Cariou, B., Hanf, R., Lambert-Porcheron, S., Zaïr, Y., Sauvinet, V., Noël, B., Flet, L., Vidal, H., Staels, B., & Laville, M. (2013) · Diabetes Care · doi:10.2337/dc12-2012 · Cited by 215
Ehrenborg, E., & Krook, A. (2009) · Pharmacological Reviews · doi:10.1124/pr.109.001560 · Cited by 213
Post-Translational Modifications of Nuclear Receptors and Human Disease
Anbalagan, M., Huderson, B., Murphy, L., & Rowan, B. G. (2012) · Nuclear Receptor Signaling · doi:10.1621/nrs.10001 · Cited by 211
PPARs and the Cardiovascular System
Hamblin, M., Chang, L., Fan, Y., Zhang, J., & Chen, Y. E. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2008.2280 · Cited by 207
Peroxisome Proliferator-Activated Receptor (PPAR) in Metabolic Syndrome and Type 2 Diabetes Mellitus
Jay, M., & Ren, J. (2007) · Current Diabetes Reviews · doi:10.2174/157339907779802067 · Cited by 196
Holst, D., Luquet, S., Nogueira, V., Kristiansen, K., Leverve, X., & Grimaldi, P. A. (2003) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(03)00071-4 · Cited by 193
Unraveling the mechanism of action of thiazolidinediones
Kahn, C. R., Chen, L., & Cohen, S. E. (2000) · Journal of Clinical Investigation · doi:10.1172/jci11705 · Cited by 191
Wagner, K.-D., & Wagner, N. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.12.001 · Cited by 189
PPARs: Regulators of Metabolism and As Therapeutic Targets in Cardiovascular disease. Part I: PPAR-α
Han, L., Shen, W.-J., Bittner, S., Kraemer, F. B., & Azhar, S. (2017) · Future Cardiology · doi:10.2217/fca-2016-0059 · Cited by 183
Self-citationSahebkar, A., Chew, G. T., & Watts, G. F. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.876992 · Cited by 180
Deeg, M. A., Buse, J. B., Goldberg, R. B., Kendall, D. M., Zagar, A. J., Jacober, S. J., Khan, M. A., Perez, A. T., Tan, M. H., & on behalf of the GLAI Study Investigators (2007) · Diabetes Care · doi:10.2337/dc06-1903 · Cited by 179
Regulation of metabolic transcriptional co‐activators and transcription factors with acute exercise
Russell, A. P., Hesselink, M. K. C., Lo, S. K., & Schrauwen, P. (2005) · The FASEB Journal · doi:10.1096/fj.04-3168fje · Cited by 177
Hansen, J. B., Zhang, H., Rasmussen, T. H., Petersen, R. K., Flindt, E. N., & Kristiansen, K. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m005567200 · Cited by 173
PPARδ as a therapeutic target in metabolic disease
Reilly, S. M., & Lee, C.-H. (2008) · FEBS Letters · doi:10.1016/j.febslet.2007.11.040 · Cited by 164
Role of Peroxisome Proliferator-activated Receptor δ/β in Hepatic Metabolic Regulation
Liu, S., Hatano, B., Zhao, M., Yen, C.-C., Kang, K., Reilly, S. M., Gangl, M. R., Görgün, C. Z., Balschi, J. A., Ntambi, J. M., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.138115 · Cited by 163
Bidirectional Relationships and Disconnects between NAFLD and Features of the Metabolic Syndrome
Wainwright, P., & Byrne, C. D. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17030367 · Cited by 162
Physiological functions of peroxisome proliferator-activated receptor β
Neels, J. G., & Grimaldi, P. A. (2014) · Physiological Reviews · doi:10.1152/physrev.00027.2013 · Cited by 161
Bastie, C. C., Holst, D., Gaillard, D., Jehl-Piétri, C., & Grimaldi, P. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.31.21920 · Cited by 160
Tao, L., Liu, H.-R., Gao, E., Teng, Z.-P., Lopez, B. L., Christopher, T. A., Ma, X.-L., Batinic-Haberle, I., Willette, R. N., Ohlstein, E. H., et al. (2003) · Circulation · doi:10.1161/01.cir.0000097003.49585.5e · Cited by 160
The PPAR-RXR Transcriptional Complex in the Vasculature: Energy in the Balance
Plutzky, J. (2011) · Circulation Research · doi:10.1161/circresaha.110.226860 · Cited by 159
Touyz, R. M., & Schiffrin, E. L. (2006) · Vascular Pharmacology · doi:10.1016/j.vph.2005.11.014 · Cited by 155
Bays, H. E., Schwartz, S. L., Littlejohn, T. W., Kerzner, B., Krauss, R. M., Karpf, D. B., Choi, Y., Wang, X., Naim, S., & Roberts, B. K. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1061 · Cited by 155
Posttranslational Modifications of PPAR‐γ: Fine‐tuning the Metabolic Master Regulator
van Beekum, O., Fleskens, V., & Kalkhoven, E. (2009) · Obesity · doi:10.1038/oby.2008.473 · Cited by 153
Myocardial lipid accumulation in patients with pressure-overloaded heart and metabolic syndrome
Marfella, R., Filippo, C. D., Portoghese, M., Barbieri, M., Ferraraccio, F., Siniscalchi, M., Cacciapuoti, F., Rossi, F., D’Amico, M., & Paolisso, G. (2009) · Journal of Lipid Research · doi:10.1194/jlr.p900032-jlr200 · Cited by 151
Girroir, E. E., Hollingshead, H. E., He, P., Zhu, B., Perdew, G. H., & Peters, J. M. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.04.086 · Cited by 150
Peroxisome proliferator-activated receptors, Metabolic Syndrome and Cardiovascular Disease
Azhar, S. (2010) · Future Cardiology · doi:10.2217/fca.10.86 · Cited by 146
Self-citationMechanisms for the Clinical Benefits of Angiotensin II Receptor Blockers
Schmieder, R. E. (2005) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2004.11.032 · Cited by 137
PPAR-gamma gene expression is elevated in skeletal muscle of obese and type II diabetic subjects
Park, K. S., Ciaraldi, T. P., Abrams-Carter, L., Mudaliar, S. R. D., Nikoulina, S. E., & Henry, R. R. (1997) · Diabetes · doi:10.2337/diab.46.7.1230 · Cited by 129
Vascular and cardiac benefits of angiotensin receptor blockers
Schiffrin, E. L. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01241-x · Cited by 128
Peroxisome proliferator-activated receptor γ C161→T polymorphism and coronary artery disease
Wang, X. (1999) · Cardiovascular Research · doi:10.1016/s0008-6363(99)00256-4 · Cited by 127
PPARs: the vasculature, inflammation and hypertension
Duan, S. Z., Usher, M. G., & Mortensen, R. M. (2009) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e328325803b · Cited by 121
The Ubiquitin-Proteasome System and Inflammatory Activity in Diabetic Atherosclerotic Plaques
Marfella, R., D’Amico, M., Esposito, K., Baldi, A., Filippo, C. D., Siniscalchi, M., Sasso, F. C., Portoghese, M., Cirillo, F., Cacciapuoti, F., et al. (2006) · Diabetes · doi:10.2337/diabetes.55.03.06.db05-0832 · Cited by 117
Pharmacological management of nonalcoholic fatty liver disease
Barb, D., Portillo-Sanchez, P., & Cusi, K. (2016) · Metabolism · doi:10.1016/j.metabol.2016.04.004 · Cited by 114
Peroxisome proliferator-activated receptors and cardiovascular remodeling
Schiffrin, E. L. (2004) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00677.2004 · Cited by 110
Functional implications of genetic variation in human PPARγ
Jeninga, E. H., Gurnell, M., & Kalkhoven, E. (2009) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2009.04.005 · Cited by 102
Inhibition of HDAC3 promotes ligand-independent PPARγ activation by protein acetylation
Jiang, X., Ye, X., Guo, W., Lu, H., & Gao, Z. (2014) · Journal of Molecular Endocrinology · doi:10.1530/jme-14-0066 · Cited by 102
PPARβ/δ potentiates PPARγ‐stimulated adipocyte differentiation
Matsusue, K., Peters, J. M., & Gonzalez, F. J. (2004) · The FASEB Journal · doi:10.1096/fj.04-1944fje · Cited by 101
Pharmacological treatment and therapeutic perspectives of metabolic syndrome
Lim, S. K., & Eckel, R. H. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9298-4 · Cited by 98
Bastie, C. C., Luquet, S. H., Holst, D., Jehl-Piétri, C., & Grimaldi, P. A. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m006450200 · Cited by 98
Peroxisome proliferator-activated receptor agonists, hyperlipidaemia, and atherosclerosis
Vosper, H., Khoudoli, G. A., Graham, T. L., & Palmer, C. N. A. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00232-2 · Cited by 95
Wallace, J. M., Schwarz, M., Coward, P., Houze, J. B., Sawyer, J. K., Kelley, K. L., Chai, A., & Rudel, L. L. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m500002-jlr200 · Cited by 94
Peroxisome proliferator-activated receptor δ: a multifaceted metabolic player
Bojic, L. A., & Huff, M. W. (2013) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32835cc949 · Cited by 93
Integrative and Systemic Approaches for Evaluating PPARβ/δ (PPARD) Function
Attianese, G. M. P. G., & Desvergne, B. (2015) · Nuclear Receptor Signaling · doi:10.1621/nrs.13001 · Cited by 92
Plutzky, J. (2000) · Current Atherosclerosis Reports · doi:10.1007/s11883-000-0067-3 · Cited by 87
The Development of INT131 as a Selective PPARγ Modulator: Approach to a Safer Insulin Sensitizer
Higgins, L. S., & Mantzoros, C. S. (2008) · PPAR Research · doi:10.1155/2008/936906 · Cited by 85
Dunn, F. L., Higgins, L. S., Fredrickson, J. O., & DePaoli, A. M. (2010) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2010.06.006 · Cited by 83
The Roles of Peroxisome Proliferator-Activated Receptors in the Metabolic Syndrome
Mansour, M. M. (2014) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-800101-1.00007-7 · Cited by 81
Peroxisome Proliferator-Activated Receptor .GAMMA. and Cardiovascular Diseases
Takano, H., & Komuro, I. (2009) · Circulation Journal · doi:10.1253/circj.cj-08-1071 · Cited by 79
Effects of the PPAR-δ agonist MBX-8025 on atherogenic dyslipidemia
Choi, Y., Roberts, B. K., Wang, X., Geaney, J. C., Naim, S., Wojnoonski, K., Karpf, D. B., & Krauss, R. M. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.10.029 · Cited by 78
Peroxisome proliferator-activated receptors for hypertension
Usuda, D. (2014) · World Journal of Cardiology · doi:10.4330/wjc.v6.i8.744 · Cited by 76
Transcriptional control of physiological and pathological processes by the nuclear receptor PPARβ/δ
Tan, N. S., Vázquez‐Carrera, M., Montagner, A., Sng, M. K., Guillou, H., & Wahli, W. (2016) · Progress in Lipid Research · doi:10.1016/j.plipres.2016.09.001 · Cited by 76
Unraveling the Effects of PPARβ/δ on Insulin Resistance and Cardiovascular Disease
Vázquez‐Carrera, M. (2016) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2016.02.008 · Cited by 73
The current role of thiazolidinediones in diabetes management
Rizos, C. V., Kei, A. A., & Elisaf, M. (2016) · Archives of Toxicology · doi:10.1007/s00204-016-1737-4 · Cited by 71
Telmisartan: just an antihypertensive agent? A literature review
Destro, M., Cagnoni, F., Dognini, G. P., Galimberti, V., Taietti, C., Cavalleri, C., & Galli, E. G. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.632367 · Cited by 65
Peroxisome Proliferator-Activated Receptors and the Cardiovascular System
Chen, Y. E., Fu, M., Zhang, J., Zhu, X., Lin, Y., Akinbami, M. A., & Song, Q. (2003) · Vitamins and hormones · doi:10.1016/s0083-6729(03)01005-7 · Cited by 50
Obesity and Metabolic Syndrome
Vega, G. L. (2005) · American Academy of Pediatrics eBooks · doi:10.1542/9781581106220-part01-obesity · Cited by 49
Discovery of INT131: A selective PPARγ modulator that enhances insulin sensitivity
Taygerly, J. P., McGee, L. R., Rubenstein, S. M., Houze, J. B., Cushing, T. D., Li, Y., Motani, A. S., Chen, J., Frankmoelle, W. P., Ye, G., et al. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.11.058 · Cited by 49
Metabolic actions of angiotensin receptor antagonists: PPAR-γ agonist actions or a class effect?
Ernsberger, P. R., & Koletsky, R. J. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.11.008 · Cited by 47
Lee, D. H., Hu, H., Choi, K., Mantzoros, C. S., & Kim, Y. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00569.2011 · Cited by 45
Angiotensin II, PPAR-Gamma and atherosclerosis
Kintscher, U. (2004) · Frontiers in bioscience · doi:10.2741/1225 · Cited by 42
Tian, L., Wang, C., Hagen, F. K., Gormley, M., Addya, S., Soccio, R. E., Casimiro, M. C., Zhou, J., Powell, M. J., Xu, P., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2371 · Cited by 41
Roberts, L. D., Hassall, D. G., Winegar, D. A., Haselden, J. N., Nicholls, A. W., & Griffin, J. L. (2009) · Genome Medicine · doi:10.1186/gm115 · Cited by 38
PPARβ in macrophages and atherosclerosis
Chinetti, G., & Staels, B. (2016) · Biochimie · doi:10.1016/j.biochi.2016.12.008 · Cited by 37
The obesity epidemic in the USA — no end in sight?
Seidell, J. C., & Halberstadt, J. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.121 · Cited by 35
GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes
Cariou, B., & Staels, B. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.954034 · Cited by 34
Blaschke, F., Caglayan, E., & Hsueh, W. A. (2006) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2006.06.001 · Cited by 30
Yong, E., Li, J., & Liu, M. H. (2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3282f64542 · Cited by 28
The Role of PPARδ Signaling in the Cardiovascular System
Ding, Y., Yang, K. D., & Yang, Q. (2014) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-800101-1.00014-4 · Cited by 23
INT-131, a PPARgamma agonist for the treatment of type 2 diabetes.
Kintscher, U., & Goebel, M. (2009) · PubMed · Cited by 17
Telmisartan as a metabolic sartan for targeting vascular failure
Inoue, T., & Node, K. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.8.1397 · Cited by 16
The Anti-Atherogenic Effects of Thiazolidinediones
Stojanovska, L., Honisett, S. Y., & Komesaroff, P. A. (2007) · Current Diabetes Reviews · doi:10.2174/157339907779802058 · Cited by 14
PPARγ mutations, lipodystrophy and diabetes
Astapova, O., & Leff, T. (2014) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2014-0033 · Cited by 12
Use of fibrates in clinical practice: Queensland Lipid Group consensus recommendations
Hamilton‐Craig, I. R., Kostner, K., Woodhouse, S. P., & Colquhoun, D. (2012) · International Journal of Evidence-Based Healthcare · doi:10.1111/j.1744-1609.2012.00275.x · Cited by 8
Cited by
Lipid Metabolism in Regulation of Macrophage Functions
Yan, J., & Horng, T. (2020) · Trends in Cell Biology · doi:10.1016/j.tcb.2020.09.006 · Cited by 553
Szilagyi, J. T., Avula, V., & Fry, R. C. (2020) · Current Environmental Health Reports · doi:10.1007/s40572-020-00279-0 · Cited by 328
Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors
Francque, S., Szabo, G., Abdelmalek, M. F., Byrne, C. D., Cusi, K., Dufour, J.-F., Roden, M., Sacks, F., & Tacke, F. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00366-5 · Cited by 316
PPAR-γ signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets
Chen, H., Tan, H., Wan, J., Zeng, Y., Wang, J., Wang, H., & Lu, X. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108391 · Cited by 311
Wagner, N., & Wagner, K.-D. (2020) · Cells · doi:10.3390/cells9112367 · Cited by 271
Metadata
- Authors
- Han, L., Shen, W.-J., Bittner, S., Kraemer, F. B., & Azhar, S.
- Venue
- Future Cardiology
- Publisher
- Informa UK Limited
- Published
- 2017-05
- Volume
- 13
- Issue
- 3
- Pages
- 279-296
- ISSN
- 1479-6678 (ISSN-L)
- 1744-8298
- OpenAlex
- W2621670189
- Cited by
- 256
- References
- 151
- FWCI
- 6.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.